Results 251 to 260 of about 8,509,826 (346)

Serotonergic modulators in Alzheimer's disease: a hope in the hopeless condition

Chemistry &Biodiversity, Accepted Article.
Alzheimer disease (AD) is the main cause of dementia worldwide. AD is a progressive brain neurodegenerative disease due to genetic and environmental factors that induce a progressive accumulation of intracellular hyperphosphorylated tau protein and extracellular amyloid protein (Aβ).
Ali I. Al-Gareeb, Morkoss Fakhry, Ali K. Albuhadily, Athanasios Alexiou, Marios Papadakis, Gaber El-Saber Batiha   +5 more
wiley   +1 more source

Heart rate variability response to alcohol, placebo, and emotional picture cue challenges: Effects of 0.1‐Hz stimulation [PDF]

, 2008
Evgeny Vaschillo, Marsha E. Bates, Bronya Vaschillo, Paul M. Lehrer, Tomoko Udo, Eun‐Young Mun, Suchismita Ray   +6 more
openalex   +1 more source

Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application

Chronic Diseases and Translational Medicine, EarlyView.
Donanemab, approved by the U.S. FDA in July 2024, targets amyloid plaques in the brain to treat Alzheimer's disease in patients with mild cognitive impairment or mild dementia. ABSTRACT Substantial research has been conducted to identify an efficient treatment for Alzheimer's disease (AD).
Nandhini Jayaprakash, Karthikeyan Elumalai   +1 more
wiley   +1 more source

Evaluation of NaTto Red Yeast Rice on Regulating Blood Lipid (ENTRY) Study: A Multicenter, Double‐Placebo, Double‐Blinded, Randomized Controlled Trial in Chinese Adults

Chronic Diseases and Translational Medicine, EarlyView.
Study flow chart of the ENTRY study. ABSTRACT Background Statins are the first line of treatment for dyslipidemia, but their side effects often reduce medication compliance. Natto and red yeast rice are natural ingredients with lipid‐lowering effects.
Shufeng Chen, Fangchao Liu, Jinyue Li, Fengchao Liang, Jianxin Li, Jie Cao, Donghua Liu, Keyong Huang, Hongfan Li, Xiangfeng Lu, Jianfeng Huang, Dongfeng Gu   +11 more
wiley   +1 more source

P0789 CIMETIDINE, CISAPRIDE, BOTH, OR NEITHER FOR INFANTILE ESOPHAGITIS: SYMPTOMATIC RESPONSE TO 4M RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED THERAPY IN 100 BABIES.

, 2004
S. R. Orenstein, Theresa M. Shalaby, S. F. Kelsey, Eric Frankel   +3 more
openalex   +1 more source

Don’t ask, Don’t tell? Revealing placebo responses to research participants and patients [PDF]

, 2008
Francis J. Keefe, Amy P. Abernethy, Jane L. Wheeler, Glenn Affleck   +3 more
openalex   +1 more source

Placebo response in pediatric migraine [PDF]

, 2008
Stephen R. Daniels
openalex   +1 more source

GDF15 Analogues Acting as GFRAL Ligands

ChemMedChem, EarlyView.
Considering the great importance of the GDF15/GRAL/RET signalling pathway, this review focuses on GDF15‐derived analogues able to act either as GFRAL agonists or antagonists, investigating their possible pharmacological applications in the treatment of GDF15‐related conditions, such as obesity and diabetes (agonist), or cancer‐induced nausea and ...
Andrea Di Santo, Livio Tarchi, Gianluca Villa, Giovanni Castellini, Valdo Ricca, Roberta Squecco, Anna Maria Papini, Feliciana Real‐Fernandez, Paolo Rovero   +8 more
wiley   +1 more source

Why we need more research into the placebo response in psychiatry. [PDF]

Psychol Med, 2020
Huneke NTM, van der Wee N, Garner M, Baldwin DS.   +3 more
europepmc   +1 more source

Consistency of Response to Sumatriptan/Naproxen Sodium in a Placebo-Controlled, Crossover Study [PDF]

, 2009
RB Lipton, DW Dodick, Adelman Ju, R. G. Kaniecki, SE Lener, J A White, AC Nelsen   +6 more
openalex   +1 more source